GenSight Biologics S.A. (GSGTF)
USD 0.24
(0.0%)
USD 0.24
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 39.8 Million EUR | 3.28% |
| 2022 | 38.53 Million USD | -5.09% |
| 2021 | 40.6 Million USD | 6.99% |
| 2020 | 37.94 Million USD | 84.42% |
| 2019 | 20.57 Million USD | 86.21% |
| 2018 | 11.05 Million EUR | 120.01% |
| 2017 | 5.02 Million EUR | 60.46% |
| 2016 | 3.13 Million EUR | -54.7% |
| 2015 | 6.91 Million EUR | 63.08% |
| 2014 | 4.23 Million EUR | 122.31% |
| 2013 | 1.9 Million EUR | 1399.9% |
| 2012 | 127.08 Thousand EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 43.8 Million EUR | 6.27% |
| 2023 Q3 | 39.83 Million EUR | -5.02% |
| 2023 FY | 39.8 Million EUR | 3.28% |
| 2023 Q4 | 39.8 Million EUR | -0.09% |
| 2023 Q2 | 41.93 Million USD | -4.26% |
| 2022 Q3 | 41.22 Million EUR | 23.12% |
| 2022 FY | 38.53 Million USD | -5.09% |
| 2022 Q1 | 37.32 Million EUR | -8.21% |
| 2022 Q2 | 33.47 Million EUR | -10.3% |
| 2022 Q4 | 41.22 Million EUR | 0.0% |
| 2021 Q3 | 40.65 Million EUR | 17.97% |
| 2021 Q4 | 40.65 Million EUR | -0.0% |
| 2021 Q2 | 34.46 Million EUR | 0.0% |
| 2021 FY | 40.6 Million USD | 6.99% |
| 2021 Q1 | 34.46 Million EUR | -3.22% |
| 2020 FY | 37.94 Million USD | 84.42% |
| 2020 Q4 | 35.61 Million EUR | 0.0% |
| 2020 Q3 | 35.61 Million EUR | 29.01% |
| 2020 Q2 | 27.6 Million EUR | -0.0% |
| 2020 Q1 | 27.6 Million EUR | 25.68% |
| 2019 Q4 | 21.96 Million EUR | 0.0% |
| 2019 Q1 | 15.64 Million EUR | 19.33% |
| 2019 Q2 | 15.64 Million EUR | 0.01% |
| 2019 Q3 | 21.96 Million EUR | 40.41% |
| 2019 FY | 20.57 Million USD | 86.21% |
| 2018 Q1 | 8.16 Million EUR | 13.1% |
| 2018 Q4 | 13.1 Million EUR | 0.0% |
| 2018 FY | 11.05 Million EUR | 120.01% |
| 2018 Q3 | 13.1 Million EUR | 60.63% |
| 2018 Q2 | 8.16 Million EUR | 0.0% |
| 2017 Q3 | 7.21 Million EUR | -7.51% |
| 2017 Q2 | 7.8 Million EUR | 0.0% |
| 2017 Q1 | 7.8 Million EUR | 32.44% |
| 2017 FY | 5.02 Million EUR | 60.46% |
| 2017 Q4 | 7.21 Million EUR | 0.0% |
| 2016 Q3 | 5.89 Million EUR | 0.0% |
| 2016 Q4 | 5.89 Million EUR | 0.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 3.13 Million EUR | -54.7% |
| 2015 FY | 6.91 Million EUR | 63.08% |
| 2015 Q3 | 6.98 Million EUR | 36.25% |
| 2015 Q4 | 6.98 Million EUR | -0.0% |
| 2015 Q2 | 5.12 Million EUR | 0.0% |
| 2015 Q1 | 5.12 Million EUR | 20.96% |
| 2014 Q4 | 4.23 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 FY | 4.23 Million EUR | 122.31% |
| 2014 Q3 | 4.23 Million EUR | 0.0% |
| 2013 FY | 1.9 Million EUR | 1399.9% |
| 2012 FY | 127.08 Thousand EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | 20.818% |
| Skye Bioscience, Inc. | 14.07 Million USD | -182.827% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 32.558% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -4820.907% |
| Qrons Inc. | 1.48 Million USD | -2573.45% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -150.241% |
| CSL Limited | 18.62 Billion USD | 99.786% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 45.081% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -320.456% |
| Regen BioPharma, Inc. | 5.45 Million USD | -629.256% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 46.877% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -88946.0% |
| Rebus Holdings, Inc. | 5.24 Million USD | -659.252% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -144980.742% |
| Neon Bloom, Inc. | 1.22 Million USD | -3145.766% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -19689.574% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 25.335% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -315.361% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -9340.944% |
| SQZ Biotechnologies Company | 50.03 Million USD | 20.462% |
| Intellipharmaceutics International Inc. | 12 Million USD | -231.425% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -933.384% |
| Mesoblast Limited | 188.44 Million USD | 78.88% |
| Marizyme, Inc. | 26.67 Million USD | -49.199% |
| Genus plc | 485 Million USD | 91.794% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -581.201% |
| Pharming Group N.V. | 244.07 Million USD | 83.693% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1879.971% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -1481.67% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -947.368% |
| ContraFect Corporation | 32.53 Million USD | -22.345% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1908.774% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -939.803% |
| IMV Inc. | 37.93 Million USD | -4.922% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -237.913% |
| MultiCell Technologies, Inc. | 1617.67 USD | -2460228.744% |
| ONE Bio Corp. | 27.49 Million USD | -44.749% |
| Accustem Sciences Inc. | 1.07 Million USD | -3587.784% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 48.59% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -1781.735% |
| Q BioMed Inc. | 8.13 Million USD | -389.368% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 52.011% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -673.411% |
| Biomind Labs Inc. | 1.49 Million USD | -2555.791% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 66.476% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -340.159% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -116.264% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -2675.722% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -27909.43% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -592.677% |
| GB Sciences, Inc. | 5.41 Million USD | -634.648% |
| Alpha Cognition Inc. | 7.16 Million USD | -455.496% |
| HST Global, Inc. | 593.59 Thousand USD | -6604.931% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -3060.755% |
| Halberd Corporation | 728.71 Thousand USD | -5361.639% |
| Enzolytics Inc. | 365.26 Million USD | 89.104% |
| Agentix Corp. | 2.51 Million USD | -1485.307% |
| Resverlogix Corp. | 67.39 Million USD | 40.946% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -4645.258% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 91.055% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -2222.054% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -60.834% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -234.367% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -985.9% |
| AVAX Technologies, Inc. | 3.99 Million USD | -896.558% |
| Zenith Capital Corp. | 27.56 Thousand USD | -144265.048% |
| Genscript Biotech Corporation | 1.32 Billion USD | 96.998% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -16576.863% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -965.794% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -5745.772% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -1367.746% |
| Kadimastem Ltd | 3.5 Million USD | -1035.564% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -59366.001% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -8464.684% |
| LadRx Corporation | 2.2 Million USD | -1708.657% |
| Cell Source, Inc. | 15.8 Million USD | -151.792% |
| Regen BioPharma, Inc. | 5.45 Million USD | -629.256% |
| NovAccess Global Inc. | 7.86 Million USD | -406.314% |
| Affymax, Inc. | 8.87 Million USD | -348.653% |
| Itoco Inc. | 1.65 Million USD | -2307.524% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1839.982% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -557.96% |
| Mobile Lads Corp. | 1.31 Million USD | -2930.079% |
| CytoDyn Inc. | 127.89 Million USD | 68.88% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -95117.589% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -2440.895% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -260.335% |
| SYBLEU INC | 681.41 Thousand USD | -5740.804% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -552.255% |
| International Stem Cell Corporation | 5.27 Million USD | -654.216% |
| Bioxytran, Inc. | 3.24 Million USD | -1124.804% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -6259.768% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -762.008% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 2.917% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -78.756% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1865.057% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -626.543% |
| Neutra Corp. | 973.52 Thousand USD | -3988.219% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -37.17% |
| PureTech Health plc | 125.58 Million USD | 68.308% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -959.321% |
| IXICO plc | 1.9 Million USD | -1994.415% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -93.872% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 61.48% |
| CSL Limited | 18.62 Billion USD | 99.786% |
| Cellectis S.A. | 249.36 Million USD | 84.04% |